All News

Expert shares key upcoming sessions at the American Diabetes Association 85th Scientific Sessions.

Discover essential tips for sunburn prevention and treatment, insect bite protection, and effective remedies for outdoor fun with family.

When no contraindications are present, most cases can be managed well with nonsteroidal anti-inflammatory drugs.

At the 2025 Oncology Pharmacists Connect (OPC) meeting, Courtney Cavalieri, PharmD, BCOP, presented clinical trial findings in gastrointestinal (GI) cancers—including colon, gastric, pancreatic, and metastatic colorectal cancer—that highlight the expanding role of immunotherapy and targeted treatments.

At the 2025 Oncology Pharmacists Connect (OPC) meeting, Mya Tran, PharmD, BCOP, highlights the clinical promise, operational challenges, and evolving role of pharmacists in implementing precision medicine and genomics-driven cancer care.

Victoria Nacher, PharmD, BCOP, offers key insights about the evolving treatment landscape for hematologic malignancies.

Its approval was based on data from a 3-year trial that enrolled patients with alkaptonuria.

Janet Espirito, PharmD, discusses real-world outcomes from a large community oncology study showing that patients with BRAF-mutated melanoma—including those with brain metastases—experienced similar benefit from frontline immune checkpoint inhibitor (ICI) therapy.

With robust pipelines, cell therapy remains the major driver for drug development.

Following robust progression-free survival indications in the phase 3 inMIND trial, the FDA granted approval to tafasitamab-cxix in combination with standard-of-care lenalidomide and rituximab for patients with relapsed or refractory follicular lymphoma.

Diet influences blood pressure, cholesterol levels, and overall heart function.

In today’s rapidly evolving health care landscape, pharmacists are playing an increasingly vital role in patient care—but many policymakers remain unaware of the full scope of their expertise and contributions.

The emergence of biomarkers plays a critical role in the growing success of treatment.

Tim Mok, PharmD, BCOP, BCPS, discusses emerging advancements in treatment of leukemia and lymphoma.

New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies.

In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.

When infected with SARS-CoV-2, the virus that causes COVID-19, higher levels of proinflammatory cytokines are released in men compared with women, leading to more severe disease.

Lenacapavir becomes the first and only twice-yearly option for HIV prevention.

Combining omega-3 supplements with exercise enhances immune response and alleviates tooth infections, offering new insights into managing apical periodontitis.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Accurate utility estimates are critical to providing a comprehensive view of quality of life for children impacted by pneumococcal disease.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Step up and speak out to break down barriers to health care and address social determinants of health.

New research reveals a significant link between type 2 diabetes, obesity, and fatty liver disease.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

The FDA approves garadacimab-gxii, a treatment for hereditary angioedema (HAE), offering convenient monthly self-injections for patients 12 years and older.